RAPT THERAPEUTICS, INC. (RAPT) News

RAPT THERAPEUTICS, INC. (RAPT): $17.06

0.58 (+3.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RAPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 373

in industry

Filter RAPT News Items

RAPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RAPT News Highlights

  • RAPT's 30 day story count now stands at 27.
  • Over the past 22 days, the trend for RAPT's stories per day has been choppy and unclear. It has oscillated between 1 and 9.
  • The most mentioned tickers in articles about RAPT are NOV, PRE and LVTX.

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT THERAPEUTICS INC that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that its abstract from its ongoing Phase 1/2 study of FLX475 as monotherapy and in combination with pembrolizumab in cancer pati

Yahoo | December 1, 2022

Have you been able to find a good deal on RAPT Therapeutics Inc.’s shares?

In Wednesday’s session, RAPT Therapeutics Inc. (NASDAQ:RAPT) marked $17.84 per share, down from $18.38 in the previous session. While RAPT Therapeutics Inc. has underperformed by -2.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RAPT fell by -45.26%, with highs and lows ranging from $40.74 to […]

US Post News | November 24, 2022

Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick

RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Yahoo | November 22, 2022

RAPT Therapeutics Slips 9% After Pricing Public Offering

Shares of RAPT Therapeutics, Inc. (RAPT) are down more than 9% Friday morning at $19.26.

RTT News | November 18, 2022

RAPT Therapeutics Tanks on $75M Public Offering

Shares of clinical-stage biopharmaceutical company RAPT Therapeutics (NASDAQ:RAPT) are sliding in the pre-market session today after RAPT announced the pricing of its underwritten public offering of ~4.05 million shares. The company is offering shares at $18.50 apiece for gross proceeds of about $75 million. Further, RAPT has granted underwriters a 30-day option to purchase an additional 608,108 shares. The offer is anticipated to close on November 22. RAPT shares have now declined nearly 45% year-to-date and short interest in the stock remains elevated at about 13.6%.

TipRanks | November 18, 2022

Is RAPT Therapeutics Inc. (NASDAQ:RAPT) stock a better investment at this time?

Currently, RAPT Therapeutics Inc.’s (RAPT) stock is trading at $19.23, marking a fall of -9.76% from last night’s close. At this price, the stock is -52.80% below its 52-week high of $40.74 and 95.13% above its 52-week low of $9.85. Based on the past 30-day period, the stock price is -22.31% below the high and […]

US Post News | November 18, 2022

RAPT Therapeutics stock slide on pricing ~$75M stock offering

RAPT Therapeutics (RAPT) shares are down 7.6% after-hours after the firm has priced its previously announced underwritten public offering of 4,054,055 shares of its common stock at a…

Seeking Alpha | November 18, 2022

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the pricing of its previously announced underwritten public offering of 4,054,055 shares of its common stock at a price to the public of $18.50 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be $75 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have been granted...

GlobeNewswire | November 17, 2022

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that it has commenced an underwritten public offering of $75 million of its common stock. In addition, RAPT expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock on the same terms and conditions. All of the shares of common stock are being offered by RAPT. The proposed offering is subject to market conditions, and there can be no assurance as to whether or whe...

GlobeNewswire | November 17, 2022

RAPT Therapeutics announces $75M stock offering

RAPT Therapeutics (RAPT) said Thursday it is launching a public offering of its common stock worth $75 million.In addition, RAPT expects to grant the underwriters of the offering a…

Seeking Alpha | November 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6551 seconds.